Table: q1_q4_2020_prescription_drugs_intro_to_market , manufacturer_name like F*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Ferring Pharmaceuticals	55566100201	ORTIKOS(Budesonide) extended release capsules 6mg	2020-07-20	1200.0000	None	1	800000	None	None	2018-10-04	None	1	Ferring Pharmaceuticals Inc. acquired the Rights to Distribute Ortikos in the US from SUN on October 4, 2019	Sources 1. ORTIKOS [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 2. Crohn’s & Colitis Foundation. The Facts About Inflammatory Bowel Diseases. November 2014. 3. Crohn’s & Colitis Foundation. Living with Crohn’s Disease. Available at: https://www.crohnscolitisfoundation.org/sites/default/files/legacy/assets/pdfs/living-with-crohnsdisease.pdf. Last accessed: May 2020. 4. Crohn’s & Colitis Foundation. Overview of Crohn’s Disease. Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/overview. Last accessed: May 2020.	None
Ferring Pharmaceuticals	55566102001	ORTIKOS(Budesonide) extended release capsules 9mg	2020-07-20	1200.0000	None	1	800000	None	None	2019-10-04	None	1	Ferring Pharmaceuticals Inc. acquired the Rights to Distribute Ortikos in the US from SUN on October 4, 2019	Sources 1. ORTIKOS [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 2. Crohn’s & Colitis Foundation. The Facts About Inflammatory Bowel Diseases. November 2014. 3. Crohn’s & Colitis Foundation. Living with Crohn’s Disease. Available at: https://www.crohnscolitisfoundation.org/sites/default/files/legacy/assets/pdfs/living-with-crohnsdisease.pdf. Last accessed: May 2020. 4. Crohn’s & Colitis Foundation. Overview of Crohn’s Disease. Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/overview. Last accessed: May 2020.	None
Fresenius Kabi USA LLC	63323082520	Decitabine for Injection 50 mg/vial	2020-04-20	394.0000	None	1	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA believes is otherwise in the public domain or publicly available, as of the date of this submission. (2) Fresenius Kabi USA’s marketing and pricing plans for this product are not in the public domain or otherwise publicly available. Consistent with the relevant statutes and regulations, Fresenius Kabi USA has left the “marketing and pricing plan description” data field blank. (3) Fresenius Kabi USA does not believe the estimated number of patients with a condition for which this product may be prescribed in the United States, consistent with its label, is in the public domain. Further, Fresenius Kabi USA does not know this information and has not put this information in the public domain. As a result, Fresenius Kabi USA has left the “estimated number of patients” data field blank. (4) The applicable dates were when Fresenius Kabi was granted a license to distribute the product in the United States. Fresenius Kabi does not own the regulatory approvals for the drug. The terms of the applicable deal are confidential, and therefore, will not be disclosed.	None
Fresenius Kabi USA LLC	63323072910	Micafungin Sodium Inj. Lyophilized 100 mg 10mL	2020-05-08	1870.0000	None	1	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA believes is otherwise in the public domain or publicly available, as of the date of this submission. (2) Fresenius Kabi USA’s marketing and pricing plans for this product are not in the public domain or otherwise publicly available. Consistent with the relevant statutes and regulations, Fresenius Kabi USA has left the “marketing and pricing plan description” data field blank. (3) Fresenius Kabi USA does not believe the estimated number of patients with a condition for which this product may be prescribed in the United States, consistent with its label, is in the public domain. Further, Fresenius Kabi USA does not know this information and has not put this information in the public domain. As a result, Fresenius Kabi USA has left the “estimated number of patients” data field blank. (4) The applicable dates were when Fresenius Kabi was granted a license to distribute the product in the United States. Fresenius Kabi does not own the regulatory approvals for the drug. The terms of the applicable deal are confidential, and therefore, will not be disclosed.	None
Fresenius Kabi USA LLC	63323072810	Micafungin Sodium Inj. Lyophilized 50 mg 10mL	2020-05-08	935.0000	None	1	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA believes is otherwise in the public domain or publicly available, as of the date of this submission. (2) Fresenius Kabi USA’s marketing and pricing plans for this product are not in the public domain or otherwise publicly available. Consistent with the relevant statutes and regulations, Fresenius Kabi USA has left the “marketing and pricing plan description” data field blank. (3) Fresenius Kabi USA does not believe the estimated number of patients with a condition for which this product may be prescribed in the United States, consistent with its label, is in the public domain. Further, Fresenius Kabi USA does not know this information and has not put this information in the public domain. As a result, Fresenius Kabi USA has left the “estimated number of patients” data field blank. (4) The applicable dates were when Fresenius Kabi was granted a license to distribute the product in the United States. Fresenius Kabi does not own the regulatory approvals for the drug. The terms of the applicable deal are confidential, and therefore, will not be disclosed.	None
Fresenius Kabi USA LLC	63323057486	Icatibant Injection 30 mg per 3 mL pack of 1	2020-10-21	5083.2600	None	1	1	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA believes is otherwise in the public domain or publicly available, as of the date of this submission. (2) Fresenius Kabi USA’s marketing and pricing plans for this product are not in the public domain or otherwise publicly available. Consistent with the relevant statutes and regulations, Fresenius Kabi USA has left the “marketing and pricing plan description” data field blank. (3) Fresenius Kabi USA does not believe the estimated number of patients with a condition for which this product may be prescribed in the United States, consistent with its label, is in the public domain. Further, Fresenius Kabi USA does not know this information and has not put this information in the public domain. As a result, Fresenius Kabi USA has left the “estimated number of patients” data field blank. (4) The applicable dates were when Fresenius Kabi was granted a license to distribute the product in the United States. Fresenius Kabi does not own the regulatory approvals for the drug. The terms of the applicable deal are confidential, and therefore, will not be disclosed.	None
Fresenius Kabi USA LLC	63323057493	Icatibant Injection 30 mg per 3 mL pack of 3	2020-10-21	15249.7800	None	1	1	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA believes is otherwise in the public domain or publicly available, as of the date of this submission. (2) Fresenius Kabi USA’s marketing and pricing plans for this product are not in the public domain or otherwise publicly available. Consistent with the relevant statutes and regulations, Fresenius Kabi USA has left the “marketing and pricing plan description” data field blank. (3) Fresenius Kabi USA does not believe the estimated number of patients with a condition for which this product may be prescribed in the United States, consistent with its label, is in the public domain. Further, Fresenius Kabi USA does not know this information and has not put this information in the public domain. As a result, Fresenius Kabi USA has left the “estimated number of patients” data field blank. (4) The applicable dates were when Fresenius Kabi was granted a license to distribute the product in the United States. Fresenius Kabi does not own the regulatory approvals for the drug. The terms of the applicable deal are confidential, and therefore, will not be disclosed.	None